LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.44 -6.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.44

Máximo

0.47

Métricas clave
By Trading Economics
Ingresos	-9.9M -48M
Ventas	1.8M 13M
Margen de beneficios	-362.728
Empleados	144
EBITDA	-10M -45M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+653.06% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-418M 129M
Apertura anterior	6.82
Cierre anterior	0.44

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 mar 2026, 19:08 UTC

Noticias de Eventos Importantes

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13 mar 2026, 18:48 UTC

Ganancias

Principales Movimientos del Mercado

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13 mar 2026, 16:47 UTC

Noticias de Eventos Importantes

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

13 mar 2026, 18:49 UTC

Noticias de Eventos Importantes

The Iran War Could Upend AI. Here's How. -- Barrons.com

13 mar 2026, 18:24 UTC

Noticias de Eventos Importantes

Impact of Middle East Conflict on TotalEnergies Activities

13 mar 2026, 18:00 UTC

Noticias de Eventos Importantes

Is War Good For the Economy? -- WSJ

13 mar 2026, 17:23 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13 mar 2026, 16:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13 mar 2026, 16:38 UTC

Noticias de Eventos Importantes

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13 mar 2026, 16:34 UTC

Adquisiciones, fusiones, absorciones

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13 mar 2026, 16:33 UTC

Adquisiciones, fusiones, absorciones

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13 mar 2026, 16:32 UTC

Adquisiciones, fusiones, absorciones

EQT Completes Exit From Galderma

13 mar 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 16:15 UTC

Noticias de Eventos Importantes

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

13 mar 2026, 16:11 UTC

Charlas de Mercado

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

13 mar 2026, 16:00 UTC

Noticias de Eventos Importantes

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

13 mar 2026, 15:48 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

653.06% repunte

Estimación a 12 Meses

Media 3.69 USD 653.06%

Máximo 15 USD

Mínimo 0.3 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.